Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsENGN +0.59%12 Current Ratio is 12.57 as of Apr. 2026, which is at its 10-year median of 12.57. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, enGene Therapeutics ranks better than 82.99% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. enGene Therapeutics's current ratio for the quarter that ended in Apr. 2026 was 12.57.
enGene Therapeutics has a current ratio of 12.57. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for enGene Therapeutics's Current Ratio or its related term are showing as below:
ENGN'
s Current Ratio Range Over the Past 10 Years
Min: 1.25 Med: 12.57 Max: 42.8
Current: 12.57
During the past 6 years, enGene Therapeutics's highest Current Ratio was 42.80. The lowest was 1.25. And the median was 12.57.
ENGN's Current Ratio is ranked better than 82.99% of 1405
companies
in the Biotechnology industry
Industry Median: 3.83
vs ENGN: 12.57
enGene Therapeutics (NAS:ENGN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
enGene Therapeutics Current Ratio Related Terms
enGene Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENGN vs VTVT, GUTS, VXRT: Current Ratio Comparison
For the Biotechnology subindustry, enGene Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (ENGN) has a Current Ratio of 12.57 as of Apr. 2026. This is near median its historical median of 12.57. Over the past decade, enGene Therapeutics' Current Ratio has ranged from 1.25 to 42.80. According to the industry distribution chart, enGene Therapeutics ranks #239 out of 1405 companies in the Biotechnology industry, placing it in the top 17%.
Is enGene Therapeutics' Current Ratio too high?
enGene Therapeutics' current Current Ratio of 12.57 is near median its 10-year median of 12.57. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 42.80. The Biotechnology industry median Current Ratio is 3.83. enGene Therapeutics' value of 12.57 is 228.2% above this industry median. Based on the distribution chart, enGene Therapeutics ranks #239 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Current Ratio compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #239 out of 1405 companies for Current Ratio. This places enGene Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.83. enGene Therapeutics' value of 12.57 is 228.2% above this benchmark. Historically, enGene Therapeutics' own Current Ratio has ranged from 1.25 to 42.80 over the past decade. While the company's 10-year median is 12.57 vs. the industry median of 3.83, enGene Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enGene Therapeutics's current Current Ratio of 12.57 is 228.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enGene Therapeutics's current Current Ratio is 12.57, which is near median its own 10-year median of 12.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current Current Ratio of 12.57. The current Current Ratio is 12.57, which is near median its 10-year median of 12.57 and 228.2% above the Biotechnology industry median of 3.83. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current Current Ratio is 12.57 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score
Get the complete analysis for ENGN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENGN has been successfully added to your 
